Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Up 24.5% – Still a Buy?

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) shares were up 24.5% during mid-day trading on Monday . The stock traded as high as $15.45 and last traded at $15.05. Approximately 392,691 shares traded hands during trading, a decline of 62% from the average daily volume of 1,044,757 shares. The stock had previously closed at $12.09.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on QNRX shares. Wall Street Zen raised shares of Quoin Pharmaceuticals to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Quoin Pharmaceuticals in a research report on Monday, December 1st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Quoin Pharmaceuticals presently has a consensus rating of “Sell”.

Quoin Pharmaceuticals Trading Up 24.5%

The company has a fifty day simple moving average of $13.80 and a 200-day simple moving average of $10.13. The company has a market capitalization of $12.64 million, a PE ratio of -0.47 and a beta of 1.58.

Quoin Pharmaceuticals (NASDAQ:QNRX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($6.71) EPS for the quarter, missing the consensus estimate of ($6.36) by ($0.35). On average, equities analysts predict that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -2.05 EPS for the current fiscal year.

Insider Buying and Selling at Quoin Pharmaceuticals

In other news, Director Dennis Langer purchased 15,152 shares of the business’s stock in a transaction dated Tuesday, October 14th. The stock was acquired at an average price of $8.49 per share, for a total transaction of $128,640.48. Following the acquisition, the director directly owned 15,153 shares of the company’s stock, valued at approximately $128,648.97. This represents a 1,515,200.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 13.46% of the stock is currently owned by company insiders.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.